Cargando…

Tocilizumab therapy for COVID-19: A comparison of subcutaneous and intravenous therapies

BACKGROUND: The release of pro-inflammatory cytokines, resulting in cytokine storm syndrome, contributes to the morbidity and mortality associated with COVID-19 disease. This study aimed to compare the effects of intravenous (IV) and subcutaneous (SC) tocilizumab, an IL-6 receptor antagonist, on res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaminski, Monica A., Sunny, Subin, Balabayova, Khayala, Kaur, Avneet, Gupta, Aanchal, Abdallah, Marie, Quale, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521212/ https://www.ncbi.nlm.nih.gov/pubmed/33002613 http://dx.doi.org/10.1016/j.ijid.2020.09.1447

Ejemplares similares

Comparison of Tocilizumab vs Baricitinib in Clinical Outcomes Among Hospitalized Patients With COVID-19: Experience From a Public Hospital System in New York City
por: Sunny, Subin, et al.
Publicado: (2023)

Is remdesivir safe in patients with renal impairment? Experience at a large tertiary urban medical center
por: Sunny, Subin, et al.
Publicado: (2022)

Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries
por: Lauper, Kim, et al.
Publicado: (2018)

Correction: Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries
Publicado: (2019)

Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2019)

Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study
por: Mekinian, Arsène, et al.
Publicado: (2023)

Correction: Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study
Publicado: (2023)

Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)
por: Burmester, Gerd R, et al.
Publicado: (2016)

Carbapenem-Resistant Klebsiella pneumoniae in Large Public Acute-Care Healthcare System, New York, New York, USA, 2016–2022
por: Lee, Jennifer, et al.
Publicado: (2023)

Sustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis
por: Ogata, Atsushi, et al.
Publicado: (2015)

Comparison of oral, intravenous, and subcutaneous fluid therapy for resuscitation of calves with diarrhea
por: Doré, V., et al.
Publicado: (2019)

Efficacious switching from subcutaneous to intravenous tocilizumab in patients with non-infectious non-anterior uveitis
por: Leclercq, Mathilde, et al.
Publicado: (2023)

Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study
por: Darloy, Jean, et al.
Publicado: (2019)

Phase III Study of the Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis
por: Ogata, Atsushi, et al.
Publicado: (2014)

Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis
por: Strand, Vibeke, et al.
Publicado: (2018)

Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open‐Label Extension of a Randomized Clinical Trial
por: Emery, Paul, et al.
Publicado: (2020)

Use of subcutaneous tocilizumab to prepare intravenous solutions for COVID-19 emergency shortage: Comparative analytical study of physicochemical quality attributes
por: Navas, Natalia, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single‐Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate
por: Paccaly, Anne J., et al.
Publicado: (2020)

Predictive Factors for Rheumatoid Arthritis Flare After Switching From Intravenous to Subcutaneous Formulation of Tocilizumab in Real-World Practice
por: Ahn, Soo Min, et al.
Publicado: (2022)

Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous Tocilizumab
por: Negoescu, Andra F., et al.
Publicado: (2014)

Subcutaneous Tocilizumab May Be Effective in Refractory Fibromyalgia Patients
por: Tang, Kuo-Tung, et al.
Publicado: (2023)

Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies
por: Canessa, Clementina, et al.
Publicado: (2016)

Comparison of Anakinra and Tocilizumab in Anticytokine Therapy in the Treatment of Coronavirus Disease-2019
por: Ozkan, Feyza, et al.
Publicado: (2022)

Cytomegalovirus Viremia, Pneumonitis, and Tocilizumab Therapy
por: van Duin, David, et al.
Publicado: (2011)

Administrative risk quantification of subcutaneous and intravenous therapies in Italian centers utilizing the Failure Mode and Effects Analysis approach
por: Ponzetti, Clemente, et al.
Publicado: (2016)

Pulse Therapy With Corticosteroids and Intravenous Immunoglobulin in the Management of Severe Tocilizumab-Resistant COVID-19: A Report of Three Clinical Cases
por: Sheianov, Mikhail V, et al.
Publicado: (2020)

Tocilizumab for Covid-19 — The Ongoing Search for Effective Therapies
por: Huang, Edmund, et al.
Publicado: (2020)

Tocilizumab in COVID-19 therapy: who benefits, and how?
por: Yang, Chengliang, et al.
Publicado: (2021)

Tocilizumab in COVID-19 therapy: who benefits, and how?
por: Neumann, Avidan U, et al.
Publicado: (2021)

Preference for Subcutaneous Injection or Intravenous Infusion of Biological Therapy Among Italian Patients With SLE
por: Falanga, Marina, et al.
Publicado: (2018)

On the Subcutaneous Injection of Blood, Infusion (Subcutaneous) and Intravenous Transfusion
por: Oehler,, et al.
Publicado: (1888)

A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)
por: Burmester, Gerd R, et al.
Publicado: (2014)

Real-world evidence on methotrexate-free subcutaneous tocilizumab therapy in patients with rheumatoid arthritis: 24-week data from the SIMPACT study
por: Nagy, György, et al.
Publicado: (2022)

Hydroxychloroquine and tocilizumab therapy in COVID-19 patients—An observational study
por: Ip, Andrew, et al.
Publicado: (2020)

Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients
por: Marfella, R., et al.
Publicado: (2020)

Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis
por: Ruperto, Nicolino, et al.
Publicado: (2021)

Subcutaneous tocilizumab in the management of non-infectious uveitis in children: a brief report
por: Burlo, Francesca, et al.
Publicado: (2023)

Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA
por: Abdallah, Hisham, et al.
Publicado: (2016)

Intravenous methylprednisolone with or without tocilizumab in patients with severe COVID-19 pneumonia requiring oxygen support: A prospective comparison
por: Hamed, Dujana Mostafa, et al.
Publicado: (2021)

The Use of Single Therapy With Tocilizumab Versus Combination Therapy With Remdesivir and Tocilizumab in SARS-CoV-2 Patients in El Paso, Texas
por: Almaghlouth, Nouf K, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8t0bdjdbec9uih1kicn6vi4tdk